{
    "clinical_study": {
        "@rank": "28575", 
        "arm_group": {
            "arm_group_label": "Treatment (combination chemotherapy, DLI)", 
            "arm_group_type": "Experimental", 
            "description": "INDUCTION CHEMOTHERAPY: Patients receive fludarabine phosphate IV over 1 hour QD for 5 days and cytarabine IV over 4 hours for 5 days. G-CSF 5 mcg/kg will be started at day14 if day14 bone marrow does not have >5% leukemic blasts. Treatment may continue for 1 or 2 courses at the discretion of the treating physician.\nALLOGENEIC CELLULAR THERAPY: Patients undergo irradiated Donor Lymphocyte Infusion (DLI) of 3 x 10^8 CD3+ cells/kg at 8 weeks. Patients with stable disease may repeat irradiated DLI every 8-12 weeks in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This pilot clinical trial studies if cells donated by a close genetic relative can help keep\n      acute myeloid leukemia (AML) from coming back after standard chemotherapy induces a complete\n      remission. Blood cells obtained from a donor include a variety of blood cells that may\n      trigger the patient's immune system to react against AML cells."
        }, 
        "brief_title": "AML Therapy With Irradiated Allogeneic Cells", 
        "completion_date": {
            "#text": "January 2020", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Adult Acute Megakaryoblastic Leukemia (M7)", 
            "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", 
            "Adult Acute Monoblastic Leukemia (M5a)", 
            "Adult Acute Monocytic Leukemia (M5b)", 
            "Adult Acute Myeloblastic Leukemia With Maturation (M2)", 
            "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", 
            "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", 
            "Adult Acute Myeloid Leukemia With Del(5q)", 
            "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", 
            "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", 
            "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", 
            "Adult Acute Myelomonocytic Leukemia (M4)", 
            "Adult Erythroleukemia (M6a)", 
            "Adult Pure Erythroid Leukemia (M6b)", 
            "Recurrent Adult Acute Myeloid Leukemia", 
            "Untreated Adult Acute Myeloid Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Congenital Abnormalities", 
                "Leukemia", 
                "Leukemia, Erythroblastic, Acute", 
                "Leukemia, Megakaryoblastic, Acute", 
                "Leukemia, Monocytic, Acute", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelomonocytic, Acute", 
                "Leukemia, Myelomonocytic, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Toxicity of haploidentical allogeneic cellular therapy in patients in complete remission\n      (CR) (or CR with incomplete platelet recovery [CRp]) after induction chemotherapy with\n      fludarabine (fludarabine phosphate)-cytarabine.\n\n      II. Efficacy of haploidentical allogeneic cellular therapy in patients in CR (or CRp) after\n      induction chemotherapy with fludarabine-cytarabine (remission rates at 6, 12, 18, 24\n      months).\n\n      SECONDARY OBJECTIVES:\n\n      I. Immunologic parameters before and after haploidentical therapy: host anti-leukemia T\n      cells; host regulatory T cells.\n\n      OUTLINE:\n\n      INDUCTION CHEMOTHERAPY: Patients receive fludarabine phosphate intravenously (IV) over 1\n      hour once daily (QD) for 5 days and cytarabine IV over 4 hours for 5 days. Treatment may\n      continue for 1 or 2 courses at the discretion of the treating physician.\n\n      ALLOGENEIC CELLULAR THERAPY: Patients undergo irradiated donor lymphocyte infusion (DLI) of\n      3 x 10^8 cluster of differentiation (CD)3+ cells/kg at 8 weeks. Patients with stable disease\n      may repeat irradiated DLI every 8-12 weeks in the absence of disease progression or\n      unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up periodically for up to 2\n      years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically proven non-M3 AML:\n\n               -  Refractory/relapsed AML OR\n\n               -  Initial diagnosis of AML in patient >= 60 years old\n\n          -  Total bilirubin =< 1.5 times upper limit of normal (ULN) institutional limits (unless\n             Gilbert's disease)\n\n          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase\n             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])\n             =< 2.5 X institutional ULN\n\n          -  Cardiac left ventricular ejection fraction (LVEF) >= 35%\n\n          -  Serum creatinine =< 1.5 mg/dl\n\n          -  Any organ dysfunction thought to be secondary to disease will be considered\n             separately and the patient will be included at the investigators discretion\n\n          -  Patients must give informed consent\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 3\n\n          -  Must have a potential haploidentical donor (parent, sibling, child)\n\n          -  A patient is eligible for second enrollment (allo-cellular therapy) if all of the\n             following inclusion criteria are met:\n\n          -  Patient must have documented CR or CRp after 1 or 2 cycles of fludarabine +\n             cytarabine\n\n          -  Patient must not be a candidate for an allo-hematopoietic stem cell transplant (HSCT)\n\n          -  Patient must have a partially (>= 3/6 class I antigen) human leukocyte antigen\n             (HLA)-matched (by serology or low resolution deoxyribonucleic acid [DNA] testing)\n             relative able to serve as a donor\n\n          -  Patients must not have active uncontrolled infections, other medical or\n             psychological/social conditions that might increase the likelihood of patient adverse\n             effects or poor outcomes\n\n          -  Total bilirubin < 1.5 times upper limit of normal (ULN) institutional limits (unless\n             Gilbert's disease)\n\n          -  AST(SGOT)/ALT(SGPT) =< 2.5 X institutional ULN\n\n          -  Serum creatinine < 2.0 mg/dl\n\n          -  ECOG performance status =< 2\n\n          -  DONOR: donor must be related to patient and be partially (>= 3/6 antigen) HLA-matched\n\n          -  DONOR: donor must meet all New Brunswick Affiliated Hospitals (NBAH) requirements for\n             hematopoietic stem cell donation, including:\n\n          -  DONOR: age >= 18 years old\n\n          -  DONOR: white blood cells (WBC) 4.0-10.0 x 10^3/mm^3\n\n          -  DONOR: platelet count 150,000 to 440,000/mm^3\n\n          -  DONOR: hemoglobin/hematocrit; 12.5-18 g/dl, 38 to 54%\n\n          -  DONOR: not pregnant or lactating\n\n          -  DONOR: not human immunodeficiency virus (HIV)-1, HIV-2, hepatitis C virus (HCV),\n             hepatitis B core or human T-lymphotropic virus (HTLV)-I/II seropositive; hepatitis B\n             surface antigen (HB S ag) (-); meet other infectious disease screening criteria\n             utilized by NBAH Blood Center\n\n          -  DONOR: no uncontrolled infections, other medical or psychological/social conditions,\n             or medications that might increase the likelihood of patient or donor adverse effects\n             or poor outcomes\n\n          -  DONOR: meet other blood bank criteria for blood product donation (as determined by\n             NBAH Blood Center screening history and laboratory studies)\n\n        Exclusion Criteria:\n\n          -  History of current or prior medical problems that the investigator feels will prevent\n             administration of therapy or assessment of response due to excess toxicity\n\n          -  Patients with known active central nervous system (CNS) leukemia will be excluded\n             from this clinical study\n\n          -  Known HIV-positive patients are excluded from the study\n\n          -  Patients may not be pregnant or breast feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02105116", 
            "org_study_id": "021208", 
            "secondary_id": [
                "NCI-2013-02408", 
                "Pro2013002693", 
                "021208", 
                "P30CA072720"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (combination chemotherapy, DLI)", 
                "description": "Given IV", 
                "intervention_name": "fludarabine phosphate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "2-F-ara-AMP", 
                    "Beneflur", 
                    "Fludara"
                ]
            }, 
            {
                "arm_group_label": "Treatment (combination chemotherapy, DLI)", 
                "description": "Given IV", 
                "intervention_name": "cytarabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ARA-C", 
                    "arabinofuranosylcytosine", 
                    "arabinosylcytosine", 
                    "Cytosar-U", 
                    "cytosine arabinoside"
                ]
            }, 
            {
                "arm_group_label": "Treatment (combination chemotherapy, DLI)", 
                "description": "Undergo infusion of donor lymphocytes", 
                "intervention_name": "donor lymphocytes", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Treatment (combination chemotherapy, DLI)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Treatment (combination chemotherapy, DLI)", 
                "description": "Given IV", 
                "intervention_name": "G-CSF", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Filgrastim", 
                    "Neupogen\u00ae", 
                    "G-CSF"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Fludarabine monophosphate", 
                "Vidarabine", 
                "Fludarabine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 2, 2014", 
        "location": {
            "contact": {
                "email": "strairrk@cinj.rutgers.edu", 
                "last_name": "Roger Strair, MD,PhD", 
                "phone": "732-235-7298"
            }, 
            "facility": {
                "address": {
                    "city": "New Brunswick", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "08903"
                }, 
                "name": "Rutgers Cancer Institute of New Jersey"
            }, 
            "investigator": {
                "last_name": "Roger Strair", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "AML Therapy With Irradiated Allogeneic Cells", 
        "overall_official": {
            "affiliation": "Rutgers Cancer Institute of New Jersey", 
            "last_name": "Roger Strair, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Response rate, determined by allogeneic cell therapy-related mortality", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Patients will be scored as being in continuous remission at 2 years or having relapsed sooner.", 
                "measure": "Response rate, determined by duration of complete remission", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02105116"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Calculated using Kaplan-Meier estimation method. Corresponding 95% confidence interval will be provided.", 
            "measure": "Progression free survival probability for CR", 
            "safety_issue": "No", 
            "time_frame": "At 2 years"
        }, 
        "source": "Rutgers, The State University of New Jersey", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Cancer Institute (NCI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Rutgers Cancer Institute of New Jersey", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Rutgers, The State University of New Jersey", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}